Cambridge/Boston, MA, USA – 18th January 2024 – Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins, Inc., a growing biotechnology company that utilizes computational de...

Dr. Stein is an industry leader with over 35 years of experience in drug development BOSTON, MA, October 4, 2023  –  AI Proteins, Inc. a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today...

Mr. Beerman will lead corporate and operational strategy to pioneer miniprotein therapeutics Mr. Alles brings over 30 years of pharmaceutical industry leadership to provide strategic counsel as Chairman of the Board BOSTON, MA, August 8, 2023  – AI Proteins, Inc., a...

Appointees include world-renowned bioinformatics expert Prof. Charlotte Deane and veterans in drug development and the FDA approval process, including Dr. Eric Rowinsky. BOSTON, MA, May 31, 2023—AI Proteins, Inc., a growing biotechnology company that utilizes...

Noah D. Beerman, a veteran of the biopharmaceutical industry with significant experience in growing and financing companies, joins AI Proteins as COO, and Xavier Michelet, Ph.D., formerly at MiNK Therapeutics with expertise in leading R&D allogeneic cell therapy...

Company moves offices and labs to Fenway biotech hub to support its pioneering approach to engineering novel proteins for drug development. BOSTON, MA, December 14, 2022—AI Proteins (“AIP”), the biotechnology company bringing a novel approach to therapeutic...

Company to focus on the rapid development of miniproteins tailor-made for therapeutics, driving down costs and shortening the time required to develop safer, more effective medicines.  BOSTON, MA, November 3, 2022  – AI Proteins, the biotechnology company using...